Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis
Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis
About this item
Full title
Author / Creator
Publisher
London: BMJ Publishing Group Ltd and Association of Clinical Pathologists
Journal title
Language
English
Formats
Publication information
Publisher
London: BMJ Publishing Group Ltd and Association of Clinical Pathologists
Subjects
More information
Scope and Contents
Contents
BackgroundOsteoprotegerin (OPG) and receptor activator of nuclear factor κ B ligand (RANKL) play a critical role in the regulation of bone turnover, but the relative importance of these two cytokines in the pathogenesis of postmenopausal osteoporosis is controversial.AimTo investigate the relationship between circulating levels of OPG, RANKL, bone...
Alternative Titles
Full title
Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_858287607
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_858287607
Other Identifiers
ISSN
0021-9746
E-ISSN
1472-4146
DOI
10.1136/jcp.2010.086595
